Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 616 AL 630

Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis

Gao Y, Liu Y, Li Y.

Adv Clin Exp Med. 2024 Nov;33(11):1179-1187. doi: 10.17219/acem/176051.

Unraveling Amentoflavone's Therapeutic Potential in Alzheimer's Disease: A Preclinical Assessment

Singh S, Agrawal N, Goyal A.

Comb Chem High Throughput Screen. 2024;27(13):1851-1860. doi: 10.2174/0113862073301291240229102657.

Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy

Wong CYJ, Baldelli A, Hoyos CM, Tietz O, Ong HX, Traini D.

Drug Deliv Transl Res. 2024 Jul;14(7):1776-1793. doi: 10.1007/s13346-024-01558-1. Epub 2024 Mar 5.

Protein-protein interaction network analysis for the identification of novel multi-target inhibitors and target miRNAs against Alzheimer's disease

Kumar V, Roy K.

Adv Protein Chem Struct Biol. 2024;139:405-467. doi: 10.1016/bs.apcsb.2023.11.005. Epub 2024 Feb 15.

Recent advances in the total synthesis of galantamine, a natural medicine for Alzheimer's disease

Cheng B, Wang Q, An Y, Chen F.

Nat Prod Rep. 2024 Jul 17;41(7):1060-1090. doi: 10.1039/d4np00001c.

Molecular hybridization: a powerful tool for multitarget drug discovery

de Sena Murteira Pinheiro P, Franco LS, Montagnoli TL, Fraga CAM.

Expert Opin Drug Discov. 2024 Apr;19(4):451-470. doi: 10.1080/17460441.2024.2322990. Epub 2024 Mar 8.

Nanotechnology-based delivery of therapeutics through the intranasal pathway and the blood-brain barrier for Alzheimer's disease treatment

Boyetey MB, Choi Y, Lee HY, Choi J.

Biomater Sci. 2024 Apr 16;12(8):2007-2018. doi: 10.1039/d3bm02003g.

Involvement of mitochondria in Alzheimer's disease pathogenesis and their potential as targets for phytotherapeutics

Maruthiyodan S, Mumbrekar KD, Guruprasad KP.

Mitochondrion. 2024 May;76:101868. doi: 10.1016/j.mito.2024.101868. Epub 2024 Mar 9.

Resveratrol: Protective Agent Against Alzheimer's Disease

Subhan I, Siddique YH.

Cent Nerv Syst Agents Med Chem. 2024;24(3):249-263. doi: 10.2174/0118715249287167240222081517.

Drug Design for Alzheimer's Disease: Biologics vs. Small Molecules

Weaver DF.

Curr Alzheimer Res. 2024;20(12):821-826. doi: 10.2174/0115672050301583240307114452.

The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Tolar M, Hey JA, Power A, Abushakra S.

Int J Mol Sci. 2024 Feb 27;25(5):2727. doi: 10.3390/ijms25052727.

Insights on the Use of Transgenic Mice Models in Alzheimer's Disease Research

Pádua MS, Guil-Guerrero JL, Prates JAM, Lopes PA.

Int J Mol Sci. 2024 Feb 28;25(5):2805. doi: 10.3390/ijms25052805.

Proximity-Induced Pharmacology for Amyloid-Related Diseases

Bertran-Mostazo A, Putriūtė G, Álvarez-Berbel I, Busquets MA, Galdeano C, Espargaró A, Sabate R.

Cells. 2024 Mar 4;13(5):449. doi: 10.3390/cells13050449.

Lecanemab Questions

Nadeau SE.

Neurology. 2024 Apr 9;102(7):e209320. doi: 10.1212/WNL.0000000000209320. Epub 2024 Mar 14.

Lecanemab for Alzheimer Disease: Is It Worth It?

Nelson SE, Lopez OL.

Neurology. 2024 Apr 9;102(7):e209265. doi: 10.1212/WNL.0000000000209265. Epub 2024 Mar 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias